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Abstract
 
CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been
widely used as a marker for mature DCs. Recently, we reported the recombinant expression of
the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble
form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be
blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine
experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of
soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even
when the EAE was induced a second time, CD83-treated mice were protected, indicating a
long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in
different therapeutic settings. Most important, even when the treatment was delayed until the
disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition,
also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease
symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in
the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive
role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune
disorders in vivo.
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Introduction
 
Human CD83 is a 45-kD glycoprotein and a member of
the immunoglobulin superfamily (1–3). CD83 expression is
induced by inflammatory cytokines and the up-regulation
of CD83 together with the costimulatory molecules such as
CD80 and CD86 during DC maturation, suggest an impor-
tant role of CD83 in the induction of specific immune
responses. For a long time, CD83 has been used as the best
surface marker for mature DCs (4). DCs are the most potent
APCs of the immune system and act as “nature’s adjuvant”
in inducing T cell–mediated immunity (5). In their immature
stage, DCs reside in peripheral tissues and are specialized in
antigen uptake. During maturation they change their phe-
notype and migrate to lymphoid organs, were they trigger
the antigen-specific T cell responses (6).
The cDNA sequence of human CD83 has been known
for quite some time and recently the cloning of murine
CD83, which shares an amino acid identity of 63% with
the human CD83, hinting at a conserved function, has
been reported (7, 8). However, the functional importance
of CD83 was unknown.
The first hints of a possible biological role for CD83 came
from experiments where DCs were virus infected. In this
respect, we reported the lysosomal degradation of CD83 in
HSV-1–infected DCs that correlated with a reduced allo-
stimulatory capacity of these virus-infected DCs (9). Others
reported similar effects with measles virus– (10) and vaccinia
virus–infected DCs (11, 12). In addition, the inhibition of
CD83 mRNA export from the nucleus into the cytoplasm,
thereby blocking CD83 protein expression, also led to a
reduced T cell stimulatory capacity (13). In combination,
these data suggested a crucial role for CD83. However, this
is only based on circumstantial evidence because it is well
known that viruses interfere with several cellular aspects,
and also the inhibition of an mRNA export pathway is not
CD83 specific. The first functional role for CD83 was re-
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ported in vitro using a soluble CD83 molecule. This soluble
CD83 protein completely inhibited DC-mediated T cell
stimulation in a concentration-dependent manner (3, 14).
These data were confirmed by Scholler et al. (15), using a
CD83–Ig fusion protein. These findings gain further bio-
logical importance when viewed with the fact that a soluble
form of CD83 was detected in normal human serum and is
also released from in vitro–cultured DCs and B lymphocytes
(16). Furthermore, it has been found that the soluble form
of CD83 is present at elevated levels in a number of hema-
tological disorders including patients with chronic lympho-
cytic leukemia and mantle cell lymphoma (17). Further-
more, recently it has been reported that CD83 is essential
for the development of CD4 single positive thymocytes,
and consequently also for the generation of peripheral
CD4
 
  
 
T cells (18). Indeed, the lack of CD83 resulted in a
selective 75–90% reduction of peripheral CD4
 
  
 
T cells.
Taken together, the data described above indicate that CD83
plays an important role for T cells as well as for DCs.
Here we investigated the effect of soluble CD83 on the
murine experimental autoimmune encephalomyelitis (EAE),
a CD4
 
  
 
T cell–mediated disease model for the early in-
flammatory stage of human multiple sclerosis. Interestingly,
only three injections of soluble CD83 inhibited the paraly-
sis associated with EAE almost completely. Strikingly, this
suppressive effect was also long-lasting because mice in
which EAE was induced for a second time were still pro-
tected, whereas untreated mice were again strongly para-
lyzed. Furthermore, soluble CD83 also strongly reduced
the paralysis in a therapeutic setting. Finally, hCD83ext
treatment almost completely reduced CD45
 
  
 
cell infiltra-
tion in the brain and in the spinal cord.
 
Materials and Methods
 
Allogeneic T Cell Proliferation.
 
BM-derived DCs (BM-DCs)
were generated from C57BL/6 mice as described previously (19).
In Brief, BM cells were seeded at a density of 2 
 
  
 
10
 
6
 
/10 ml in
R10 cell culture medium. R10 culture medium was composed of
RPMI 1640 (GIBCO BRL) supplemented with 100 U/ml peni-
cillin (Sigma-Aldrich), 100 
 
 
 
g/ml streptomycin (Sigma-Aldrich),
2 mM 
 
l
 
-glutamine (Sigma-Aldrich), 50 
 
 
 
M 2-mercaptoethanol
(Sigma-Aldrich), and 10% heat-inactivated FCS (PAA Laborato-
ries GmbH). GM-CSF supernatant (1:10) from a cell line trans-
fected with the murine GM-CSF gene was used to obtain mature
DCs. At day 10 of the BM-DC culture, 4 
 
  
 
10
 
6 
 
T cells, which
were purified from pooled BALB/c lymph node cells, were
seeded together with titrated numbers of BM-DCs into a 96-well
flat-bottom plate (Falcon) for 72 h. BM-DCs were preincubated
with different concentrations of the soluble human CD83 mole-
cule (hCD83ext) or the murine CD83–Ig (mCD83–Ig) fusion
protein (Biocarta). Glutathione 
 
S
 
-transferase (GST) was used as
negative control. Cell cultures of this allogeneic MLR were then
pulsed with 1 
 
 
 
Ci/well [
 
3
 
H]methyl-thymidine (Amersham Bio-
sciences) overnight for 16 h. The plates were harvested with an
IH-110 harvester (Innotech) and filters were counted in a 1450
Microplate Counter (Wallac).
 
EAE Induction and Treatment with hCD83ext.
 
Female C57Bl/6
mice (Charles River Laboratories) were immunized s.c. with 50
 
 
 
g myelin oligodendrocyte glycoprotein (MOG) peptide 35–55
(Sigma-Genosys) in 50 
 
 
 
l H
 
2
 
O emulsified in 50 
 
 
 
l CFA that
was enriched with 10 
 
 
 
g/ml 
 
Mycobacterium tuberculosis
 
 (H37Ra;
Difco/BD Biosciences) at day 0 to induce EAE. In addition, 200
ng pertussis toxin (Pt; List/Quadratech) was administered i.p. at
days 0 and 2. EAE paralysis of mice was scored as follows: 0, no
disease; 1, tail weakness; 2, paraparesis; 3, paraplegia; 4, paraplegia
with forelimb weakness; 5, moribund or dead animals. Soluble
hCD83ext (100 
 
 
 
g/injection) was injected i.p. on days 
 
 
 
1, 1,
and 3. One group of mice received BSA (100 
 
 
 
g/injection of
Pentex-BSA; Bayer) as control protein. In the control group, the
EAE was induced without any treatment. Three mice were
treated in each group. In the therapeutic setting, soluble hCD83ext
was administered at different time points after the EAE induction
(day 3, 10, or 17), and was then given more often (every second
day or every day; see Fig. 5, A–C).
The statistical significance of differences in clinical index (day
21) between groups was analyzed using Student’s 
 
t
 
 test. Signifi-
cance was accepted if P 
 
  
 
0.05.
 
Restimulation.
 
30, or alternatively 60, d after immunization of
mice with MOG, spleens were removed for restimulation assays.
Cells were cultured in HL-1 serum-free medium supplemented
with 100 U/ml penicillin (Sigma-Aldrich), 100 
 
 
 
g/ml strepto-
mycin (Sigma-Aldrich), 2 mM 
 
l
 
-glutamine (Sigma-Aldrich), and
50 
 
 
 
M 2-mercaptoethanol (Sigma-Aldrich). MOG-specific cells
were analyzed by incubating 4 
 
  
 
10
 
5 
 
spleen cells with different
concentrations of MOG peptide in 200 
 
 
 
l HL-1/well in a 96-
well tissue culture plate. Additionally, as a control, 4 
 
  
 
10
 
5 
 
spleen
cells were stimulated with 500 U/ml IL-2 (Proleukin). As a neg-
ative control, unstimulated cultures were used. After 72 h, cul-
tures were pulsed with 0.4 Ci/mmol [
 
3
 
H]thymidine (TRA-20;
Amersham Biosciences). 12 h later, thymidine incorporation was
measured using a microplate counter (Wallac).
 
Cytokine Assays.
 
To determine the ex vivo cytokine produc-
tion, harvested splenocytes (day 12, 30, or 60) were stimulated
with different concentrations of the MOG peptide. Culture su-
pernatants were taken after 96 h and tested (either immediately or
after freezing) using commercially available sandwich ELISA kits
for INF-
 
 
 
, IL-2, IL-4, and IL-10 (BD Biosciences).
 
Neuropathology.
 
For visualization of inflammatory infiltrates,
brains and spinal cords from mice (day 12 after EAE induction)
were removed, fixed in liquid nitrogen, and stored at 
 
 
 
80
 
 
 
C.
Sections were cryoprotected in Tissue-Tek
 
®
 
 (Sakura) and sliced
sequentially with a thickness of 7 
 
 
 
m with a cryotome (Kryocut
CM 2000; Leica). Acetone-fixed cryostat sections were stained
with Mayer’s hemalaun solution (Merck) and examined by light
microscopy (Leica). Immunohistological staining was performed
using an immunoperoxidase detection system in a wet chamber.
Acetone-fixed sections were incubated in PBS. Endogenous per-
oxidase was blocked by incubating sections in 3% H
 
2
 
O
 
2
 
. The pri-
mary antibody was an anti–mouse CD45 antibody (clone 30G12;
provided by L. Sorokin, Lund University, Lund, Sweden). As
secondary antibody, biotinylated goat anti–rat IgG and streptavi-
din horseradish peroxidase (Biocare Medical) were used. To visu-
alize antigens, sections were incubated with AEC Chromogene
Substrate (Vector Laboratories), mounted in Aqua Tex (Roth),
and covered with a coverslip.
 
Results
 
Inhibition of DC-mediated Murine Allogeneic T Cell Prolifer-
ation Using Human or Murine CD83.
 
To test whether or
not soluble human CD83 is able to inhibit murine DC- 
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mediated T cell proliferation, hCD83ext was compared
with the murine CD83–Ig fusion protein. On day 10
of culture, mouse BM-DCs were either incubated with
hCD83ext or with the mCD83Ig, and their stimulatory ca-
pacity was tested in an allogeneic MLR. As shown in Fig.
1, both the human as well as the murine CD83 molecule
were able to completely abrogate allogeneic murine T cell
proliferation, suggesting a similar functional capacity. In
contrast, DCs cultured in the presence of GST (as negative
control) did not suppress T cell proliferation. These results
clearly show that one can use soluble human CD83 to in-
hibit murine DC-mediated T cell responses.
 
Soluble CD83 Inhibits EAE In Vivo.
 
The murine EAE
model was used to determine the influence of hCD83ext in
vivo. Therefore, we injected hCD83ext (100 
 
 
 
g/i.p. injec-
tion) on day 
 
 
 
1, 1, and 3, and EAE was induced on day 0
by injecting MOG/Pt, with a second injection of Pt on day
2. Strikingly, hCD83ext almost completely inhibited the
MOG-induced paralysis, whereas BSA-treated and un-
treated control mice developed strong paralysis, reaching a
maximum level at days 18–24 (Fig. 2 A, left). Furthermore,
when EAE was induced for a second time on day 28,
hCD83ext-treated mice were still completely protected,
whereas BSA-treated and untreated mice developed paraly-
sis symptoms once again (Fig. 2 A, right). This strongly
suggests that the inhibitory effects induced by soluble CD83
are long-lasting in vivo.
 
The Inhibitory Effect of Soluble CD83 Is Dose Dependent.
 
To establish whether or not this inhibitory effect is dose
dependent, different concentrations of soluble CD83 were
administered. As shown in Fig. 2 B, the effect of soluble
CD83 is clearly dose dependent. The best inhibition was
clearly observed at a concentration of 100 
 
 
 
g/injection.
No inhibition was observed at a dose of 10 
 
 
 
g/injection,
whereas 50 
 
 
 
g/injection showed an intermediate effect.
 
Soluble CD83-treated Mice Show a Strongly Inhibited Cyto-
kine Production and a Reduced T Cell Proliferation.
 
To gain
mechanistic insights into the inhibitory effects of soluble
CD83, spleens were removed from treated and untreated
mice on days 12, 30 (Fig. 2 A, 1. EAE), and 60 (Fig. 2 A, 2.
EAE), and spleen cells were restimulated with MOG pep-
tide at different concentrations for 72 h to determine their
cytokine production and their antigen-specific prolifera-
tion. As shown in Fig. 3 A, IFN-
 
  
 
production was strongly
Figure 1. Soluble human CD83 as well as murine CD83–Ig inhibit mu-
rine allogeneic T cell proliferation. 4   106 T cells were seeded together
with titrated numbers of BM-DCs into a 96-well flat-bottom plate for 72
h. BM-DCs were preincubated with different concentrations of the soluble
human CD83 molecule (hCD83ext) or the murine CD83–Ig (mCD83–Ig)
fusion protein. Cell cultures of this allogeneic MLR were then pulsed with
1  Ci/well [3H]methyl-thymidine for 16 h. The plates were harvested and
the filters were counted. The data show that human (hCD83ext) as well as
murine CD83 (mCD83–Ig) completely block murine T cell proliferation.
GST, which was purified in the same way as hCD83ext, was used as a con-
trol protein. These experiments were performed at least five times. Data
presented here represent a typical experiment.
Figure 2. Three doses of soluble CD83 protect mice from EAE. (A, left)
100  g hCD83ext (or BSA as control) were injected i.p. on days  1, 1,
and 3. EAE was induced by s.c. injection of MOG peptide emulsified in
CFA enriched with M. tuberculosis at day 0 as described in Materials and
Methods. In addition, 200 ng Pt was administered i.p. on days 0 and 2.
hCD83ext almost completely inhibited the paralysis. In contrast, BSA-
treated and untreated mice developed strong disease symptoms. (A, right)
On day 28, EAE was induced a second time by immunizing the mice
with MOG peptide as described above. Strikingly, mice which were
treated only three times with hCD83ext were completely protected,
whereas untreated and BSA-treated mice were paralyzed. (B) Inhibitory
effect is dose dependent. hCD83ext was administered at three different
doses. The best inhibition was observed at a dose of 100  g/injection
(P   0.05). These experiments were performed at least five times. Data
presented here represent a typical experiment. n, total number of animals
used in this particular experiment; nap, total number of animals with
paralysis in this particular experiment; hcs, highest clinical score observed
in this particular experiment; do, day of onset. 
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reduced in hCD83-treated mice (harvested on day 12). IL-2,
IL-4, and IL-10 levels were very low (
 
 
 
40 pg/ml) or un-
der the detection limit (not depicted).
Next, the proliferation capacity of day 30 harvested and
then restimulated cells was analyzed. As shown in Fig. 3 B,
the proliferation capacity of cells derived from hCD83ext-
treated animals, where the EAE was induced only once, is
clearly reduced when compared with BSA-treated or un-
treated mice. Interestingly, however, hCD83ext-treated
spleen cells still proliferated in response to IL-2, indicating
that soluble CD83 does not induce a complete deletion of
T cells in general (Fig. 3 B, inset). Next, the cytokine pro-
duction of these day 30 restimulated cells was analyzed. As
shown in Fig. 3 C, IFN-
 
  
 
production was strongly reduced
in hCD83-treated mice. The same was true for the IL-10
production (Fig. 3 D), indicating that soluble CD83 does
not induce IL-10–producing regulatory T cells. IL-2 and
IL-4 production was again very low (
 
 
 
40 pg/ml) or unde-
tectable (not depicted).
Next, spleen cells harvested on day 60 and derived from
animals in which EAE was induced for a second time, were
restimulated in vitro. Poor, reduced proliferation could be
observed for all conditions, and hCD83ext-treated cells re-
sponded to a much lesser degree to IL-2 (Fig. 3 E). Also in
these experiments, cells derived from CD83-treated ani-
mals produced much less IFN-
 
  
 
and IL-10 (Fig. 3, F and
G). As seen before, IL-2 and IL-4 production was very low
(
 
 
 
40 pg/ml) or not detectable (unpublished data), indicat-
ing that soluble CD83 does not lead to a skewing of the
MOG-specific immune response from a Th1 cell to a Th2
cell response during the memory phase.
 
Soluble CD83 Inhibits CD45
 
  
 
Cell Infiltrates in the Brain
and the Spinal Cord.
 
To investigate the effect of soluble
CD83 on pathologic expression of EAE during the acute
Figure 3. Soluble CD83 inhibits cytokine production
and restimulation. To determine the ex vivo cytokine pro-
duction, splenocytes, derived from hCD83ext-treated,
BSA-treated, or untreated mice, where EAE was induced
once, were harvested on day 12. MOG-specific cells were
analyzed by incubating 4   105 spleen cells with different
concentrations of MOG peptide as described in Materials
and Methods. Culture supernatants were taken after 96 h
and analyzed. (A) hCD83ext-treated cells are strongly in-
hibited in their IFN-  production. (B) Restimulation of
spleen cells, harvested on day 30 and derived from hCD83
ext-treated, BSA-treated, or un-treated mice, where EAE
was induced once. MOG-specific cells were analyzed by
incubating 4   105 spleen cells with different concentra-
tions of MOG peptide as described in Materials and Meth-
ods. Spleen cells derived from hCD83ext-treated mice
show a clearly reduced proliferation. Additionally, as a con-
trol, 4   105 spleen cells were stimulated with 500 U/ml
IL-2. Also, hCD83ext-treated cells are still able to proliferate
in response to IL-2 (see inset at right). (C and D) Ex vivo
cytokine production of these day 30 harvested splenocytes.
(C) hCD83ext-treated cells are strongly inhibited in their
IFN-   production. (D) Also, the IL-10 production is
clearly reduced. (E) Restimulation of spleen cells harvested
on day 60 and derived from hCD83ext-treated, BSA-
treated, or untreated mice, where EAE was induced twice.
hCD83ext-treated mice show reduced proliferation capacity.
They also poorly proliferate in response to IL-2 (see inset at
right). (F and G) Ex vivo cytokine production of these day
60 harvested splenocytes. (F) IFN-  production is strongly
inhibited. (G) The same is true for the IL-10 production.
These experiments were performed at least three times.
Data presented here represent a typical experiment. 
Zinser et al.
 
349
phase of the disease (day 12), histopathological analyses were
performed. As show in Fig. 4, soluble CD83 strongly inhib-
its CD45
 
  
 
leukocyte infiltration in the brain (Fig. 4 C) as
well as in the spinal cord (Fig. 4 F). This was comparable to
naive, untreated mice (Fig. 4, A and D). In sharp contrast,
mock-treated EAE mice showed strong infiltrates in both
the brain (Fig. 4 B) as well as the spinal cord (Fig. 4 E).
 
Soluble CD83 Protects Mice from EAE also in a Therapeutic
Setting.
 
In the experimental setting shown in Fig. 2, we
clearly demonstrated that soluble CD83 has a great prophy-
lactic potential to inhibit EAE symptoms. To determine
whether or not soluble CD83 also has a therapeutic poten-
tial, EAE was induced as described above on day 0. How-
ever, the administration of soluble CD83 was postponed
until day 3 (Fig. 5 A), or even longer until day 10 (Fig. 5 B).
Strikingly, in both cases, soluble CD83 clearly reduced the
paralysis when compared with the control animals. Further-
more, to “mimic” realistic therapeutic circumstances, treat-
ment with soluble CD83 was delayed until day 17, i.e.,
when disease symptoms were fully established, and was then
applied every day until day 24. As shown in Fig. 5 C, left,
soluble CD83 clearly reduced the disease symptoms. In ad-
dition, EAE was induced a second time by immunizing the
mice with MOG peptide on day 30. Strikingly, mice that
were pretreated with soluble CD83 from day 17 until 24
showed strongly reduced disease symptoms when compared
with BSA-treated and untreated mice (Fig. 5 C, right).
 
Discussion
 
DCs act as “nature’s adjuvant” in inducing T cell–medi-
ated immunity. However, to induce potent immune re-
sponses, DCs have to mature. During this maturation step,
CD83 is rapidly up-regulated together with the costimula-
tory molecules CD80 and CD86. Although CD83 is
strongly up-regulated on mature DCs, the function of this
molecule was not known. To elucidate the mode of action
of CD83, we previously reported the recombinant expres-
sion of the extracellular Ig domain of human CD83 (14,
20). Using this soluble CD83 molecule, we could show that
DC-mediated T cell stimulation is completely abrogated in
vitro (3, 14, 21). Furthermore, when soluble CD83 was
added to immature DCs, it inhibited DC maturation and
even when soluble CD83 was added to already fully ma-
tured DCs, it still led to a down-modulation of CD83 itself
and to a block of T cell stimulation. These data strongly in-
dicated a functional role for CD83 in DC biology.
Here we report the function of soluble CD83 in vivo using
the murine EAE as a model disease for the early inflammatory
stage of human multiple sclerosis. First, we showed that solu-
ble, human CD83 is also able to inhibit murine T cell stimu-
lation in vitro
 
.
 
 Both human and murine CD83 molecules
blocked allogeneic murine T cell stimulation in a concentra-
tion-dependent manner (Fig. 1), thus a similar mode of action
has been postulated for both CD83 molecules. Consequently,
human soluble CD83 was used for the mouse in vivo studies.
Strikingly, only three injections of soluble CD83 inhib-
ited the EAE symptoms almost completely (Fig. 2 A). This
effect was concentration dependent (Fig. 2 B). The effect
was even more pronounced when the EAE was induced for
a second time in the same mice. In this case, the soluble
CD83-treated mice were completely protected, whereas
control mice were once again paralyzed. This indicated a
long-lasting effect of soluble CD83, which is unlikely to be
purely due to the presence of CD83. Thus, the stimulatory
capacity of antigen-specific spleen cells was analyzed in pep-
Figure 4. Soluble CD83 inhibits CD45  cell infiltrates in the brain and the spinal cord. A and D represent naive, untreated mice as a control where
EAE was not induced. B and E represent untreated mice where EAE was induced. There is a strong CD45  cell infiltrate visible in the brain (B) as well
as in the spinal cord (E). In contrast, hCD83ext-treated mice show no or only very minor infiltrations in the brain (C) and the spinal cord (F). Mice were
analyzed on day 12 after EAE induction. These experiments were performed at least three times. Data presented here represent a typical experiment. 
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tide-specific restimulation assays. After the first EAE induc-
tion, there was a clear reduction of MOG-specific prolifera-
tion in the CD83-treated animals (Fig. 3 B). However, these
cells were not deleted because they still responded to IL-2,
although more weakly than when compared with cells
derived from BSA-treated or untreated animals. Similarly,
MOG-specific restimulation, after the induction of the sec-
ond EAE, was also reduced in cells derived from CD83-
treated animals when compared with control cells (Fig. 3 E).
However, all cells, whether treated or untreated, responded
to a much lower degree after the second EAE induction
when compared with the restimulation after the first EAE
induction. A clear difference was, however, observed when
CD83-treated cells were restimulated with IL-2. In this case,
CD83-treated cells responded rather poorly when compared
with BSA-treated or untreated cells, indicating that those
cells might be deleted. However, no signs of deletion were
observed as judged from in vitro assays (14). Nevertheless,
we cannot exclude partial deletion in vivo.
Furthermore, the cytokine production of these restimu-
lated cells was analyzed, and a strong reduction of IFN-
 
 
 
production could be observed in CD83-treated animals after
the first EAE induction (Fig. 3, A and C). This effect was
even more pronounced after the second EAE induction (Fig.
3 F). A similar reduction was observed for the IL-10 produc-
tion, excluding the induction of IL-10–producing Tr1 cells.
(Fig. 3, D and G). IL-2 production was very low (
 
 
 
40 pg/
ml) or undetectable in all samples. IL-4 production was also
very low (
 
 
 
40 pg/ml) or undetectable in all samples and
thus, a shift to Th2 cell polarization can be excluded as
a mechanism of tolerogenic immune deviation. Taken to-
gether, these data clearly show that proliferation, IFN-
 
 
 
, and
IL-10 productions are inhibited in CD83-treated mice.
Thus, the Th1 cell–specific immune response, responsible
for the EAE-associated disease symptoms, has been sup-
pressed. Taken together, none of the classical T cell toler-
ance mechanisms seem to be involved in the immunosup-
pression mediated by soluble CD83. However, this has to be
further analyzed in detail and will be the topic of a different
study. The striking effect observed in the initial experiments
with three prophylactic applications of soluble CD83, which
prevented the EAE symptoms, was very encouraging. Thus,
 
Figure 5.
 
Soluble CD83 also protects mice from EAE in a therapeutic
setting. (A) EAE was induced as shown in Fig. 2. Starting from day 3, 100
 
 
 
g hCD83ext (or BSA as control) was injected i.p. every second day until
day 29. hCD83ext almost completely inhibited the paralysis. (P 
 
  
 
0.05).
In contrast, BSA-treated animals and untreated mice developed strong
disease symptoms. (B) EAE was induced as described above, however,
hCD83ext treatment started only on day 10 and was then given every day
until day 24. Again soluble CD83 strongly reduced the paralysis in this
therapeutic setting (P 
 
  
 
0.05). BSA-treated animals and untreated mice
developed strong disease symptoms. These experiments were performed
at least three times. Data presented here represent a typical experiment.
(C) Treatment with soluble CD83 was delayed until day 17, when disease
symptoms were fully established, and was then applied every day until day
24. Soluble CD83 clearly reduced the paralysis (P 
 
  
 
0.05). In contrast,
BSA-treated animals and untreated mice developed strong, longer-lasting
symptoms. On day 30, EAE was induced a second time by immunizing
the mice with MOG peptide as described above. Strikingly, mice that
were pretreated with hCD83ext from day 17 until 24 showed reduced
disease symptoms, whereas untreated animals and BSA-treated mice
showed strong disease symptoms. These experiments were performed
three times. Data presented here represent a typical experiment. n, total
number of animals used in this particular experiment; nap, total number
of animals with paralysis in this particular experiment; hcs, highest clinical
score observed in this particular experiment; do, day of onset. 
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the therapeutic effect of this molecule was also investigated.
The data clearly show that when soluble CD83 was adminis-
tered during the initial phase of EAE induction (day 3),
which represents the immunological onset of the disease, or
at a later period (day 10), which spans the onset of the first
clinical symptoms, a clear reduction in paralysis was ob-
served. These data strongly suggest that soluble CD83 is able
to inhibit this autoimmune disorder at several different stages
of the disease. First of all, therapeutic applications of soluble
CD83 completely prevented paralysis (Fig. 2). Furthermore,
and even more important, is the fact that soluble CD83 is
also active in the therapeutic setting, be it at an early stage
during the immune induction phase, or later when the first
symptoms of paralyses were observed. Most impressive were
the effects when soluble CD83 was administered at a very
late stage, i.e., when disease symptoms were fully established
(Fig. 5 C). Thus, therapeutic intervention with soluble
CD83 has profound clinical effects. In addition, it is note-
worthy to state that soluble CD83 also exhibits a very pro-
nounced effect on inflammatory CD45
 
  
 
cell infiltrates in the
brain as well as in the spinal cord. There are almost no such
infiltrates observed in soluble CD83-treated mice (Fig. 4).
This is obviously a prerequisite to inhibit the associated pa-
thology within the neuronal system. In summary, here we
have shown for the first time that soluble CD83 inhibits
pathological autoimmune disorders in vivo and that these
data underline the therapeutic potential of this molecule in
such disorders as well as in the inhibition of transplant rejec-
tion and T cell–mediated allergies.
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